Writing in Cell Reports, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators have presented a multifaceted analysis and structure-function study of a panel of human monoclonal antibodies (hmAbs) targeting AMA1 elicited by natural Plasmodium falciparum infection in a malaria-endemic region in Mali.
In a study published in Nature Neuroscience, researchers from Tiziana Life Sciences Ltd. and collaborators investigated the potential of nasal delivery of the CD3 foralumab to reduce neuroinflammation and enhance microglial phagocytosis in a traumatic brain injury (TBI) model.
APG-777 is an anti-IL-13 humanized monoclonal antibody (mAb) designed to block Th2 inflammatory signaling mediated by the IL-13Rα1/IL-4Rα complex, while APG-990 is a fully human anti-OX40L mAb that that blocks type 1/2/3 inflammatory signaling. Apogee Therapeutics Inc. is studying the combination effects of APG-777 and APG-990 as potential therapy for atopic dermatitis (AD).
Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T cells, supports the function of inflammatory T cells, exacerbating skin dysfunction. Researchers from Astria Therapeutics Inc. presented the preclinical characterization of STAR-0310, a humanized monoclonal IgG1 antibody targeting OX40.
Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while mitigating the toxicity limitations of current monoclonal antibody therapies.
Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a cytokine secreted by epithelial cells that acts as an alarmin in response to environmental insults.
Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, from Genome & Co. Ltd. Targeting CNTN4 is a new approach that blocks the CNTN4-APP checkpoint interaction on T cells, promoting tumor cell killing, with potential use in cancers that respond poorly to conventional checkpoint inhibitors.
Helicore Biopharma Inc. has emerged from stealth with $65 million in series A financing and a focus on first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. The company’s portfolio includes GIP antibody conjugates designed to address specific obesity subpopulations.
Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI).
Malaria remains a significant global health challenge, causing over 600,000 deaths annually despite existing prevention and treatment measures. Current vaccines and monoclonal antibodies (mAbs) against Plasmodium falciparum, such as RTS,S/AS01 and R21, primarily target the central repeat region of the circumsporozoite protein (CSP) but have shown limited efficacy in completely preventing infection.
RSS
